Paper-Based Biosensors for Monitoring Binding, Blocking, and Surrogate Neutralizing Antibody Responses Against Viral Infections
Open Access
- 4 August 2026
- journal article
- review article
- Published by MDPI AG in Biosensors
- Vol. 16 (8) , 420
Abstract
Virus-specific antibody responses, including binding antibodies and neutralizing antibodies (nAbs), are important indicators of antiviral immune status after infection or immunization. They provide complementary information on antiviral humoral immunity after infection or vaccination. Antigen-binding antibodies indicate previous exposure and the magnitude of the immune response, whereas receptor-blocking and functional neutralization assays assess whether antibodies interfere with viral entry or infection. Conventional neutralization assays, such as plaque reduction neutralization tests and pseudovirus neutralization tests, provide functional information but are labor-intensive, time-consuming, biosafety-restricted, and difficult to deploy for large-scale or decentralized monitoring. Paper-based biosensors, including lateral flow assays (LFAs), microfluidic paper-based analytical devices (μPADs), and paper-based ELISA, have emerged as promising point-of-care tools owing to their low cost, portability, simple operation, and compatibility with visual or digital readouts. This review critically evaluates these platforms according to whether they measure antigen-binding antibodies, receptor-blocking activity, surrogate neutralization, or functional neutralization and summarizes the applications of these three platforms for monitoring antibody responses against SARS-CoV-2, influenza, dengue, Zika, and monkeypox viruses. Unlike previous reviews that mainly focus on general paper-based biosensor design or conventional nAb assays, this review emphasizes the distinction between antigen-binding, receptor-blocking, and surrogate neutralization readouts, and critically discusses how paper-based signals should be interpreted in relation to functional immunity. We further analyze key translational challenges, including quantitative accuracy, antigen cross-reactivity, standardization, clinical validation, regulatory positioning, and real-world implementation. Future development should combine multiplex detection, standardized calibration, digital and AI-assisted interpretation, and clinically validated assay formats. Paper-based biosensors have considerable potential for decentralized antibody monitoring and public health surveillance, but their clinical utility depends on clear assay positioning and validation against appropriate functional or reference methods.Keywords
Funding Information
- Guangdong Provincial Department of Science and Technology (2025A0505020047)
- Key Research and Development Program of Ningxia (2026BEG02026)
This publication has 127 references indexed in Scilit:
- Challenges in the development of microfluidic paper–based analytical devices (μPADs)Microchimica Acta, 2025
- Chemiluminescent lateral flow assay based on transparent nitrocellulose membraneMicrochimica Acta, 2025
- Monkeypox virus A29L protein as the target for specific diagnosis and serological analysisApplied Microbiology and Biotechnology, 2024
- Comparison of protein immobilization methods with covalent bonding on paper for paper-based enzyme-linked immunosorbent assayAnalytical and Bioanalytical Chemistry, 2024
- Sample-to-answer lateral flow assay with integrated plasma separation and NT-proBNP detectionAnalytical and Bioanalytical Chemistry, 2024
- Quantum dot fluorescent microsphere-based immunochromatographic strip for detecting PRRSV antibodiesApplied Microbiology and Biotechnology, 2024
- Innovations and Challenges in Electroanalytical Tools for Rapid Biosurveillance of SARS‐CoV‐2Advanced Materials Technologies, 2022
- Finger stick blood test to assess postvaccination SARS‐CoV‐2 neutralizing antibody response against variantsBioengineering & Translational Medicine, 2022
- Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS‐CoV‐2 neutralizing activity of seraJournal of Medical Virology, 2020
- Clinical performance of different SARS‐CoV‐2 IgG antibody testsJournal of Medical Virology, 2020